Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

The goal of this consensus initiated by the European Crohn's and Colitis Organisation
(ECCO) was to establish European consensus guidelines for the surgical treatment of …

Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked
clinical hurdle in cancer management. Chemotherapy-induced constipation (CIC) and …

Chemotherapy—induced gastrointestinal dysfunction is a common occurrence associated
with many different classes of chemotherapeutic agents. Gastrointestinal toxicity includes …

Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be
radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host …

Abstract Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the
G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have …

It is well appreciated that microbial metabolism of drugs can influence treatment efficacy.
Microbial β-glucuronidases in the gut can reactivate the excreted, inactive metabolite of …

Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with
unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). It …

Background Treament‐related diarrhoea is one of the most common and troublesome
adverse effects related to chemotherapy or radiotherapy in people with cancer. Its reported …